Red PTS STUFF Flashcards
What is Polymyalgia rheumatica
common systemic inflammatory disease that is one of the most common indications for long-term steroids. It is characterised by myalgia and muscles stiffness with preponderance to the neck, shoulder and pelvic girdle.
Who is affected by polymyalgia rheumatica
PMR is predominantly a disease of older adults and rarely presents before 50 years old. The peak prevalence is estimated between 70-80 years. Women are 2-3 times more likely to be affected than men.
Aetiology of PMR
there appears to be a pro-inflammatory response with elevated levels of IL-6, an increase in certain T-cell subsets and subclinical arterial inflammation in some patients.
Genetic and environmental factors for aetiology of PMR
Genetic: PMR, like GCA, has been associated with several human leucocyte antigen (HLA) alleles (e.g. HLA-DR4).
Environmental: the cyclical pattern of cases and peak incidence in winter months suggests an infectious trigger.
Predominant sites of inflammation for PMR
proximal articular and periarticular structures.
Pathophysiology of PMR
predominant site of inflammation includes bursae and tendons. Bursae are fluid-filled sacs that counteract the friction associated with tendons.
Despite the site of inflammation, patients still present with generalised muscle stiffness and pain, particularly in the shoulder and pelvic girdles.
Characteristic sites in the upper and lower extremities associated with PMR:
Shoulder girdle: subdeltoid/subacromial bursitis and biceps tenosynovitis.
Pelvic girdle: bursae around the greater trochanters and ischial processes. liopectineal and iliopsoas bursitis. Hamstring tendinitis and hip synovitis.
Symptoms of PMR
Bilateral shoulder and/or hip girdle pain
Stiffness and upper limb tenderness: particularly mornings
Systemic features: low-grade fever, fatigue, weight loss
Low mood
Peripheral symptoms
Signs of PMR
Reduced range of movement: shoulder, cervical spine, and hips
Inability to abduct shoulders past 90º
Synovitis and swelling
Motor exam:
GCA and PMR
10% of patients with PMR will develop GCA. Therefore, it is essential to assess for features of GCA including unilateral headache, visual changes, jaw claudication, temporal artery tenderness, scalp pain and constitutional symptoms.
Diagnosis of PMR
Age: 50 years or older at disease onset
Typical symptoms: bilateral, symmetrical shoulder and/or hip girdle pain associated with stiffness
Duration: > 2 weeks and lasting > 45 minutes at a time
Elevated inflammatory markers (ESR/CRP): supportive, but diagnosis can be made if normal
Rapid resolution of symptoms with corticosteroids: patient-reported global improvement of 70% or more within a week
Atypical features
Younger age of onset
Significant weight loss
Night pain
Neurological findings
Absence of core symptoms
Normal, or markedly elevated, inflammatory markers
Chronic onset
Investigations
FBC
UE
LFT
Autoimmune screen
Chest and shoulder x ray
Management of PMR
Start on oral prednisolone 15mg daily
After initiation - prednisolone should be reduced once symptoms are fully controlled - usually after a period of 3-4 weeks
Steroid - related complications
teroid-induced hyperglycaemia, mood changes, insomnia, gastrointestinal bleeding, immunosuppression, weight gain, cushingoid appearance, osteoporosis and adrenal cortex suppression.
Prognosis of PMR
Up to 45% of patients may not respond to steroids within the first 3-4 weeks of treatment and a more extended course of steroids may be needed.
Thankfully, there is no increased mortality associated with PMR, but relapse is common and patients may develop morbidity associated with side-effects from corticosteroids.
What is Pagets?
A chronic bone disorder that is characterised by focal areas of increased bone remodelling, resulting in overgrowth of poorly organised bone.
Also known as osteitis deformans.
Epidemiology of Pagets
- Typically affects older people (rare in under-40s)
- Commoner in temperate climates and anglo-saxons
- UK has highest prevalence in the world
Aetiology of Pagets
- Can be triggered by infections e.g. measles virus
- Linked to genetic mutations e.g. SQSTM1
RF for Pagets
- Family history
- Age >50 years
- Infection
Pathophysiology of Pagets
- Phase 1 - lytic phase
- Osteoclasts which have up to 100 nuclei aggressively demineralise the bone (x20 more than normal).
- Phase 2 - mixed phase (lytic and blastic)
- Blastic phase - rapid, disorganised proliferation of new bone tissue by a large number of osteoblasts. Collagen deposited in a haphazard way.
- Phase 3 - sclerotic phase
- New bone formation exceeds bone resorption. The bone is structurally disorganised and weak.
clinical manifestations of Pagets
Pain
Hearing loss
VIsion loss
Kyphosis - curved spine
Pelvic assymetry
Bowlegs
Investigation for Pagets
Biochemisty - ALP elevated, calcium and phosphate normal
X- ray - bone enlargement and deformity,
Bone biopsy
Management for Pagets
- Pain relief
- NSAIDs
- Anti-resorptive medication - Biphosphonates e.g. alendronic acid
- Along with calcium and vit D supplementation
- Surgery -
- Correct bone deformities
- Decompress impinged nerve
- Decrease fracture risk
Monitoring Pagets
Check the serum alkaline phosphatase (ALP) and review symptoms. Effective treatment should normalise the ALP and eliminate symptoms.
Complications for Pagets
Paget’s sarcoma (osteosarcoma)
Spinal stenosis and spinal cord compression
- Fractures
- Vision loss
- Hearing loss
- Arthritis - if any joint involvement
Definition of osteomalacia
Osteomalacia is a metabolic bone disease characterised by incomplete mineralisation of the underlying mature organic bone matrix (osteoid) following growth plate closure in adults.
This results in softening of the bones.
Results in rickets in children and osteomalacia in adults
Epidemiology of osteomalacia
- In the developed world, it is estimated that 40% of individuals over the age of 50 years are vitamin D deficient; this is the most common cause of osteomalacia.
- Fortification of foods with vitamin D and the use of vitamin supplements has greatly reduced the incidence of osteomalacia in the Western world.
Aetiology of osteomalacia
- Vitamin D
- Calcium
- Phosphate
RFs for osteomalacia
- Limited exposure to sunlight
- Dark skin
-
Dietary vitamin D deficiency
CKD
Vit D resistance
Liver dysfunction
Malabsorption
Tumour induced
Vit D activation
itamin D requires activation by the liver (25-hydroxylation) and then by the kidney (1-alpha-hydroxylation/ calcitriol). Active vitamin D raises serum calcium and phosphate by increasing intestinal absorption, as well as resorption from the bone and kidney. These electrolytes then contribute to bone mineralisation.
What does parathyroid hormone do
Stimulates resorption of Ca2+ and phosphate from bone, increases Ca2+ reabsorbtion and phosphate excretion from kidneys and also boosts 1-alpha-hydroxylase activity causing increased levels of vit D.
Pathophysiology of osteomalacia
Osteomalacia is primarily caused byvitamin D deficiencywhich can be due to reduced sunlight exposure, poor nutrition, malabsorption, liver failure, and renal failure. Occasionally osteomalacia can be caused by hypophosphataemia due to inborn errors in metabolism.
Signs of osteomalacia
Osteomalacia is primarily caused byvitamin D deficiencywhich can be due to reduced sunlight exposure, poor nutrition, malabsorption, liver failure, and renal failure. Occasionally osteomalacia can be caused by hypophosphataemia due to inborn errors in metabolism.
Symptoms of osteomalacia
- Generalised bone pain: rib, hip, pelvis, thigh and foot pain are typical
- Proximal muscle weakness
- Difficulty walking upstairs
- Muscle spasms and numbness due to hypocalcaemia
- Fracture: often secondary to mild trauma, most commonly affecting the long bones
Primary investigation for osteomalacia
Serum calcium and phosphate
Serum 25-hydroxy vitamin D
pth LEVEL
Serum ALP
GS investigation for osteomalacia
Iliac bone biopsy with double tetracycline labelling
DD for osteomalacia
- Osteoporosis
- Paget’s disease
tREATMENT OF OSTEOMALACIA
Treat underlying cause
Calcium D3 given if dietary insufficiency
If there is malabsorption or hepatic disease what do you do?
itamin D2 (ergocalciferol) or IM calcitriol. If renal disease of vitamin D resistance, then give alfacalcidol or calcitriol